Institut Pasteur - A Quoi Servent Vos Dons ?

Fondation reconnue d’utilité publique, l’Institut Pasteur est habilité à collecter des fonds pour mener à bien ses missions de recherche, de santé publique et d’enseignement. Vos dons sont versés immédiatement et sans intermédiaire aux équipes mettant en œuvre ces missions.


How ‘death’ molecules squeeze the cells out of our tissues

Most of our tissues are constantly renewed and needs to get rid of dying cells without affecting their organisation. A newly identified mechanism is responsible for the seamless exclusion of dying cells from our tissues. This process is based on the dismantling of microtubules, long fibers well known for their function during cell division and transport in the cells. Tuning microtubules stability could be used to exclude cancerous cells from our tissue despite their resistance to cell death.


The Institut Pasteur and the Institut Curie sign a new strategic agreement that holds great potential for French research

The Institut Pasteur and the Institut Curie have embarked on a new collaborative research strategy. A framework agreement was signed on June 22, 2022 between Professor Sir Stewart Cole, President of the Institut Pasteur, and Professor Thierry Philip, Chairman of the Institut Curie's Executive Board. The aim is to push the boundaries of knowledge in cancer cell biology, immunology and human genetics, including via cross-cutting approaches in the fields of biophysics and chemistry.


Conversation: capacity building to prepare for the future

Institut Pasteur Senior Executive Scientific Vice-President Christophe d'Enfert provides a brief, cross-disciplinary overview of 2021 covering capacity building, enhanced partnerships and future technologies.


Conversation: 2021, a pivotal year for the Institut Pasteur's future

Institut Pasteur Board of Governors Chairman Christian Vigouroux and President Prof. Sir Stewart Cole share their thoughts on the year's highlights. 2021 was a pivotal year poised between maintaining financial stability and supporting scientific projects.


L’Institut Pasteur et l’Institut Curie signent un nouvel accord stratégique à fort potentiel pour la recherche française

L’Institut Pasteur et l’Institut Curie s’engagent dans une nouvelle stratégie de recherche collaborative. Un accord-cadre a été signé le 22 juin 2022 entre le Pr Sir Stewart Cole, directeur général de l’Institut Pasteur et le Pr Thierry Philip, président du Directoire de l’Institut Curie. L’objectif : faire avancer les connaissances en biologie de la cellule cancéreuse, en immunologie, en génétique humaine, y compris via des approches transversales en biophysique ou en chimie.


A historic fight against emerging infectious diseases

Emerging infectious diseases result from contact between microbes and animals, with humans the most parasitized animal species. From the plague in Asia in 1894 to the current COVID-19 crisis, scientists at the Institut Pasteur have long leveraged their expertise and talent to further knowledge creation and benefit humankind.


A New Drug Target against Malaria

Malaria is a disease that continues to cause tremendous suffering and mortality in the tropics. This disease is caused by Plasmodium parasites. The species Plasmodium falciparum causes the severest and most deadly form of malaria. Scientists from Institut Pasteur studied the blood stage of the parasites and found a mechanism which could lead to new and efficient drugs against Malaria.


Une nouvelle cible médicamenteuse contre le paludisme

Le paludisme est une maladie qui continue d’engendrer d’importantes souffrances et de faire de nombreuses victimes dans les régions tropicales. Cette maladie est provoquée par les parasites du genre Plasmodium. L’espèce Plasmodium falciparum est à l’origine de la forme la plus sévère et la plus mortelle du paludisme. Des chercheurs de l’Institut Pasteur ont étudié le stade sanguin des parasites et découvert un mécanisme susceptible de conduire à la mise au point de nouveaux médicaments efficaces contre le paludisme.


Cancer: observing immune cells fighting tumors

An Institut Pasteur team has developed a microfluidic system to observe individual immune cells and model their interactions with tumors.

In a paper published in Nature Communications, Institut Pasteur scientists introduced a new method for modeling cancer immunotherapy. This approach seeks to model cancer immunotherapy in vitro using an innovative microfluidic system. The scientists successfully monitored the behavior of individual immune cells and were thus able to describe their interactions with tumor models.



S'abonner à Institut Pasteur RSS
Retour en haut